This website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
This Website Uses Cookies By closing this message or continuing to use our site, you agree to our cookie policy. Learn MoreThis website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
The U.S. Food and Drug Administration is reopening the docket from its May 2019 public hearing on cannabidiol (CBD), allowing the public and other stakeholders to submit scientific data as the agency works to close knowledge gaps on the safety and effectiveness of CBD.
The agency announced the move March 6 alongside other efforts it has taken in the areas of CBD education, research and enforcement. The FDA said it would offer updates on its progress when it announced in November 2019 that it doesn’t consider CBD to be generally recognized as safe (GRAS) to include in food products.